A novel signaling mechanism for LRP5

LRP5 的新型信号传导机制

基本信息

批准号：
10706591
负责人：
Dianqing Wu
金额：
$ 53.56万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-19 至 2027-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10706591
关键词：
Acids Address Affect Animals Back Binding Proteins Biological Biology Cause of Death Cell Surface Receptors Cell physiology Cell surface Cells Cellular biology Clinical Complex Development Diet Eicosapentaenoic Acid Embryonic Development Environmental Risk Factor Essential Fatty Acids Event Fatty Acids Fish Oils Food Genetic Health Homeostasis Human Immune Immune checkpoint inhibitor Immune system Immunologic Surveillance Immunotherapy In Vitro Infiltration Investigation Knock-out Knockout Mice Knowledge Laboratories Ligands Lipids Location Low-Density Lipoproteins MC38 Malignant Neoplasms Mediating Mus N-3 polyunsaturated fatty acid NK Cell Activation Natural Killer Cells Organogenesis Pathway interactions Phosphorylation Phosphorylation Inhibition Polyunsaturated Fatty Acids Process Proteins Proteomics Publishing Regulation Research Role Signal Transduction Signaling Molecule Specificity Testing Therapeutic Tissues Tumor Immunity WNT Signaling Pathway Wnt proteins beta catenin cancer therapy deprivation fatty acid transport follow-up glucose metabolism immunomodulatory therapies immunoregulation in vivo inhibitor insight interest lipid metabolism lipidomics metabolomics mouse model neoplastic cell novel receptor stem cell biology transcriptomics tumor tumor progression tumorigenesis uptake

项目摘要

Project Summary / Abstract: Cancer is a leading cause of death, but recent emergence of immunotherapies including the immune checkpoint inhibitors has offered promising new cancer treatment options. It is also evident that tumor immunity is highly complex and incompletely understood. The better understanding of tumor immune regulation may lead to identification of additional targets for cancer immunomodulatory therapy. In this study we will investigate the mechanism by which the cell surface receptor protein LRP5 regulates NK cell activities and tumor immunity. In our preliminary studies, we found that loss of LRP5 led to increased activation of NK cells independently of β-catenin stabilization despite LRP5 is involved in β-catenin regulation in other cells. Thus, we hypothesize that LRP5 regulates NK activation via previously uncharacterized mechanisms. Because genetic inactivation of LRP5 in NK cells suppresses tumor progression accompanied with enhanced NK activities in mice, this new mechanism is potentially of important clinical implications. Our preliminary results suggest that LRP5 may function as a fatty acid transporter leading to regulation of mTROC1 activity. In this application, we will carry out comprehensive in vitro and in vivo investigations to characterize this new mechanism for LRP5 and to determine the roles of this new mechanism in NK biology and tumor surveillance.

项目摘要 /摘要：癌症是死亡的主要原因，但最近出现了包括免疫的免疫疗法检查点抑制剂提供了承诺新的癌症治疗选择。这也证明肿瘤免疫力是高度复杂的，不完全理解。对肿瘤免疫的更好理解调节可能导致鉴定出癌症免疫调节治疗的其他靶标。在这项研究中我们将研究细胞表面受体蛋白LRP5调节NK细胞活性的机制和肿瘤免疫。在我们的初步研究中，我们发现LRP5的损失导致NK的激活增加与β-catenin稳定目的地LRP5无关的细胞参与其他细胞中的β-catenin调节。这是我们假设LRP5通过先前未表征的机制调节NK激活。因为NK细胞中LRP5的遗传失活抑制了肿瘤的进展，并伴有增强 NK活动在小鼠中，这种新机制可能具有重要的临床意义。我们的初步结果表明，LRP5可能充当脂肪酸转运蛋白，从而导致MTROC1活性的调节。在该应用程序，我们将进行全面的体外和体内调查，以表征这一新的 LRP5的机制，并确定这种新机制在NK生物学和肿瘤监测中的作用。